Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

2.7K
2.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

2.2K
2.2K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

4.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
4.7K
Ovaries01:26

Ovaries

3.5K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.

Nature communications·2026
Same author

Regulatory Guidance for the Return of Raw Genomic Data to Research Participants: A Qualitative Interview Study.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2026
Same author

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Radical resection and sentinel lymph node evaluation of mammary-like adenocarcinoma of the vulva (MLAV) with somatic BRCA1 mutation.

Gynecologic oncology reports·2025
Same author

Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers.

Clinical proteomics·2025

Related Experiment Video

Updated: May 6, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

13.8K

Ovarian cancer, version 2.2013.

Robert J Morgan1, Ronald D Alvarez, Deborah K Armstrong

  • 1From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5UCSF Helen Diller Family Comprehensive Cancer Center; 6he Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 7Vanderbilt-Ingram Cancer Center; 8The University of Texas MD Anderson Cancer Center; 9University of Washington/Seattle Cancer Care Alliance; 10Moffitt Cancer Center; 11Duke Cancer Institute; 12University of Michigan Comprehensive Cancer Center; 13Roswell Park Cancer Institute; 14Dana-Farber/Brigham and Women's Cancer Center; 15Massachusetts General Hospital Cancer Center; 16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 17Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 18Memorial Sloan-Kettering Cancer Center; 19St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 20Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 21Stanford Cancer Institute; 22Huntsman Cancer Institute at the University of Utah; and 23National Comprehensive Cancer Network.

Journal of the National Comprehensive Cancer Network : JNCCN
|October 22, 2013
PubMed
Summary

This summary covers key 2013 NCCN Guidelines updates for ovarian cancer, including intraperitoneal chemotherapy, CA-125 monitoring, and treatments for recurrent disease.

More Related Videos

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.4K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.4K

Related Experiment Videos

Last Updated: May 6, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

13.8K
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
05:35

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

2.4K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.4K

Area of Science:

  • Gynecologic Oncology
  • Clinical Practice Guidelines
  • Evidence-Based Medicine

Background:

  • The National Comprehensive Cancer Network (NCCN) Guidelines provide evidence-based recommendations for cancer care.
  • Regular updates are crucial to reflect advancements in treatment and clinical trial data.
  • Ovarian cancer management requires continuous evaluation of emerging therapies and monitoring strategies.

Purpose of the Study:

  • To highlight significant updates to the 2013 NCCN Guidelines for Ovarian Cancer.
  • To discuss the rationale behind specific guideline changes and omissions.
  • To inform clinicians about recent advancements in ovarian cancer management.

Main Methods:

  • Review of recent clinical trials and panel discussions.
  • Focus on four key areas: intraperitoneal chemotherapy, CA-125 monitoring, surveillance for rare histologies, and recurrent epithelial ovarian cancer therapy.
  • Analysis of NCCN Guidelines updates and rationale.

Main Results:

  • Key updates include changes in intraperitoneal chemotherapy protocols.
  • Refined recommendations for using CA-125 in monitoring ovarian cancer recurrence.
  • Revised surveillance strategies for less common ovarian cancer histopathologies.
  • New therapeutic options for recurrent epithelial ovarian cancer are discussed.

Conclusions:

  • The NCCN Guidelines for Ovarian Cancer have been updated to incorporate recent clinical evidence.
  • These insights provide a focused overview of critical changes impacting patient care.
  • Understanding these updates is essential for optimal management of ovarian cancer.